AVBP revenueQ3 2026$5.00M
AVBP revenue was $5.00M in fiscal Q3 2026 (ended Sep 30, 2026).
ArriVent BioPharma Inc. (AVBP) financials
For the twelve months ended Sep 30, 2026, ArriVent BioPharma Inc. reported -$169.07M of net income.
- Net income, TTM
- -$169.07M
- EPS, diluted, TTM
- -$3.51
- Cash
- $113.58M
- Market cap
- $665.2M
FY2023FY2025
AVBP revenue and earnings growth
AVBP net incomeQ3 2026-$40.31M
AVBP net income was -$40.31M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$34.98M a year earlier. For the full fiscal 2025 it was -$166.31M, compared with -$80.49M in fiscal 2024.
AVBP EPSQ3 2026-$0.81
AVBP diluted EPS was -$0.81 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.83 a year earlier. For the full fiscal 2025 it was -$4.32, compared with -$2.56 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $153.35M | $79.00M | $64.88M |
| Selling, general and admin | $24.18M | $15.30M | $9.71M |
| Operating income | -$177.53M | -$94.31M | -$74.59M |
| Net income | -$166.31M | -$80.49M | -$69.33M |
| EPS, basic | -$4.32 | -$2.56 | -$32.38 |
| EPS, diluted | -$4.32 | -$2.56 | -$32.38 |
| Diluted shares | 38.5M | 31.5M | 2.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $45.54M | $74.29M | $150.39M |
| Short-term investments | $267.28M | $144.57M | - |
| Current assets | $332.90M | $226.98M | $159.97M |
| Total assets | $333.17M | $274.94M | $163.10M |
| Current liabilities | $25.95M | $17.27M | $11.62M |
| Total liabilities | $25.95M | $17.29M | $11.80M |
| Shareholders' equity | $307.22M | $257.65M | -$153.19M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$160.59M | -$70.21M | -$55.84M |
| Investing cash flow | -$71.23M | -$192.47M | - |
| Financing cash flow | $203.06M | $186.58M | $42.86M |
| Stock-based compensation | $12.52M | $3.21M | $895.0K |
| Depreciation and amortization | -$3.03M | - | - |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.00M | - | - | - | - | - | - | - | - | - | - | - |
| Research and development | $38.90M | $42.34M | $37.62M | $32.17M | $32.17M | $27.72M | $61.29M | $20.16M | $20.09M | $21.78M | $16.98M | $20.01M |
| Selling, general and admin | $9.48M | $10.35M | $8.49M | $6.65M | $6.15M | $5.90M | $5.48M | $3.54M | $4.14M | $3.92M | $3.70M | $3.11M |
| Operating income | -$43.38M | -$52.69M | -$46.11M | -$38.82M | -$38.32M | -$33.62M | -$66.77M | -$23.70M | -$24.23M | -$25.70M | -$20.67M | -$23.12M |
| Net income | -$40.31M | -$49.89M | -$43.32M | -$35.54M | -$34.98M | -$31.40M | -$64.39M | -$20.63M | -$20.56M | -$21.87M | -$17.42M | -$21.19M |
| EPS, basic | -$0.81 | -$1.05 | -$0.96 | -$0.69 | -$0.83 | -$0.90 | -$1.90 | - | -$0.61 | -$0.65 | -$0.70 | - |
| EPS, diluted | -$0.81 | -$1.05 | -$0.96 | -$0.69 | -$0.83 | -$0.90 | -$1.90 | - | -$0.61 | -$0.65 | -$0.70 | - |
| Diluted shares | 49.5M | 47.6M | 45.1M | - | 41.9M | 35.0M | 33.9M | - | 33.6M | 33.5M | 25.0M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $113.58M | $154.68M | $62.10M | $45.54M | $112.67M | $112.77M | $49.87M | $74.29M | $282.86M | $298.67M | $317.39M | $150.39M |
| Short-term investments | $279.64M | $218.44M | $264.28M | $267.28M | $187.59M | $122.92M | $126.21M | $144.57M | - | - | - | - |
| Current assets | $416.62M | $394.17M | $348.70M | $332.90M | $321.22M | $250.15M | $185.78M | $226.98M | $292.40M | $308.51M | $327.48M | $159.97M |
| Total assets | $417.09M | $394.72M | $349.30M | $333.17M | $326.56M | $269.51M | $215.50M | $274.94M | $292.71M | $308.86M | $327.84M | $163.10M |
| Current liabilities | - | $27.84M | $25.00M | $25.95M | $21.56M | $19.64M | $12.95M | $17.27M | $15.16M | $12.10M | $9.98M | $11.62M |
| Total liabilities | $23.61M | $27.88M | $25.32M | $25.95M | $21.56M | $19.64M | $12.95M | $17.29M | $15.22M | $12.20M | $10.12M | $11.80M |
| Shareholders' equity | $393.48M | $366.84M | $323.98M | $307.22M | $305.00M | $249.87M | $202.54M | $257.65M | $277.49M | $296.66M | $317.72M | -$153.19M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.71M | -$39.58M | -$41.89M | -$30.66M | -$35.80M | -$26.12M | -$68.01M | -$16.15M | -$16.34M | -$19.09M | -$18.63M | -$14.91M |
| Investing cash flow | -$60.65M | $46.07M | $3.58M | -$71.20M | -$50.76M | $13.91M | $36.82M | - | - | - | - | - |
| Financing cash flow | $60.26M | $86.09M | $54.87M | $34.73M | $86.47M | $75.11M | $6.76M | $55.0K | $531.0K | $363.0K | $185.63M | -$1.06M |
| Stock-based compensation | $6.88M | $6.67M | $5.49M | $3.22M | $3.72M | $3.31M | $2.27M | $952.0K | $866.0K | $765.0K | $625.0K | $319.0K |
| Depreciation and amortization | -$653.0K | -$515.0K | -$559.0K | - | - | - | - | - | - | - | - | - |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -867.5% | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | -806.3% | - | - | - | - | - | - | - | - | - | - | - |
| Current ratio | - | 14.16 | 13.95 | 12.83 | 14.90 | 12.74 | 14.34 | 13.14 | 19.28 | 25.50 | 32.82 | 13.76 |
Source: XBRL data ArriVent BioPharma Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AVBP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AVBP | - | - | -$169.07M | - | $665.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
AVBP FAQ
5 questionsIs AVBP profitable?
No. ArriVent BioPharma Inc. reported a net loss of $169.07M for the twelve months ended Sep 30, 2026.How much cash and debt does AVBP have?
ArriVent BioPharma Inc. reported $113.58M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is AVBP earnings per share?
Diluted earnings per share were -$3.51 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did AVBP last report financial results?
The latest statements here come from ArriVent BioPharma Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this AVBP financial data come from?
Quantisnow builds these statements from the structured XBRL data ArriVent BioPharma Inc. files with the SEC. It is provided for information only and is not investment advice.